Arcadia Biosciences, Inc. (RKDA) — SEC Financial Statements & Analysis

Arcadia Biosciences, Inc. (RKDA) is a crude petroleum & natural gas company, incorporated in DE. Arcadia Biosciences, Inc. trades on Nasdaq as: RKDA. Arcadia Biosciences, Inc. (RKDA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Arcadia Biosciences, Inc. carries a market cap of $2.03M, a P/E ratio of -0.18x, a P/B ratio of 3.21x, a P/S ratio of 0.43x, an enterprise value of $-2.15M, and an EV/EBITDA multiple of 0.56x. On profitability, it posts a gross margin of 34.60%, an operating margin of -80.15%, a net margin of -234.53%, a Return on Equity (ROE) of -430.93%, a Return on Assets (ROA) of -162.72%, and a Return on Invested Capital (ROIC) of -96.72%. Per share, it reports EPS of $-3.72, diluted EPS of $-3.72, free cash flow per share of $-0.85, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -11.69% year-over-year, net income growth of 47.72% year-over-year, and EPS growth of -32.52% year-over-year. On the balance sheet, it maintains a current ratio of 3.49x, a quick ratio of 2.88x, working capital of $4.09M, a debt-to-equity ratio of 8.31x, a debt ratio of 0.89, an interest coverage ratio of -237.75x, free cash flow of $-2.54M (TTM), and net debt of $-4.18M. Figures sourced from SEC EDGAR.

Market Cap

$2.03M

P/E TTM

-0.18x

EPS TTM

$-3.72

P/B TTM

3.21x

ROE TTM

-430.93%

ROA TTM

-162.72%

Debt To Equity

8.31x

Free Cash Flow TTM

$-2.54M

Net Revenue TTM Growth 1Y

-11.69%

Data as of 2026-06-30 · Source: SEC EDGAR